The Caltech spinout has raised funds from investors including Heritage Medical Systems to develop treatments for neurological diseases.
US-based biopharmaceutical company Axial Biotherapeutics spun out of the Mazmanian Laboratory at California Institute of Technology (Caltech) on Wednesday with a $19.2m series A round featuring healthcare provider Heritage Medical Systems.
Investment managers Longwood Fund and Domain Associates led the round, joining venture capital firm Kairos Ventures and a group of high-net-worth individuals based in Southern California.
Axial was established to capitalise on Sarkis Mazmanian’s research, which examines the link between the human gut microbiome – genes in the trillions…